NASDAQ
INBS
Last Price
US $2.25
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Intelligent Bio Solutions Inc. cash flow to debt ratio of -3.43K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Intelligent Bio Solutions Inc.'s free cash flow has decreased 1.19% from $-9.79M last year to $-9.91M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Intelligent Bio Solutions Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Intelligent Bio Solutions Inc.'s debt has increased relative to shareholder equity from 0.14 last year to 0.21 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Intelligent Bio Solutions Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Intelligent Bio Solutions Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Intelligent Bio Solutions Inc.'s profit margin has increased (-9.08%) in the last year from -326.40% to -296.76%, signaling increasing performance
Financial risk - Short term assets vs short term liabilities.
Intelligent Bio Solutions Inc.'s short-term liabilities of $5.35M exceed its short-term assets of $4.14M, signaling financial risk
Decreasing performance - ROA.
Intelligent Bio Solutions Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Intelligent Bio Solutions Inc.'s return on equity of -174.16%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Intelligent Bio Solutions Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Intelligent Bio Solutions Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Intelligent Bio Solutions Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Intelligent Bio Solutions Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Intelligent Bio Solutions Inc.'s yearly earnings has decreased 4.06% since last year from $-10.16M to $-10.57M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Intelligent Bio Solutions Inc.'s yearly revenue has decreased -1.91% since last year from $3.11M to $3.05M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -110.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Intelligent Bio Solutions Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Intelligent Bio Solutions Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Intelligent Bio Solutions Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Intelligent Bio Solutions Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Intelligent Bio Solutions Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Intelligent Bio Solutions Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Intelligent Bio Solutions Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Intelligent Bio Solutions Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Intelligent Bio Solutions Inc. has a price-to-book ratio of 0.41x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Intelligent Bio Solutions Inc. has a price-to-sales ratio of 0.92x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-174.16%
Return on equity
ROIC: -110.43%
Valuation History
-0.17X
Price to Earnings
EV/EBITDA: 0.35X
Cash flow
Profit margin
0.00%
(FY vs FY)
Cash flow Y/Y
-45.00%
(FY vs FY)
Fair Value
Market $2.25
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.